945 related articles for article (PubMed ID: 30719763)
1. EuroInf 2: Subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson's disease.
Dafsari HS; Martinez-Martin P; Rizos A; Trost M; Dos Santos Ghilardi MG; Reddy P; Sauerbier A; Petry-Schmelzer JN; Kramberger M; Borgemeester RWK; Barbe MT; Ashkan K; Silverdale M; Evans J; Odin P; Fonoff ET; Fink GR; Henriksen T; Ebersbach G; Pirtošek Z; Visser-Vandewalle V; Antonini A; Timmermann L; Ray Chaudhuri K;
Mov Disord; 2019 Mar; 34(3):353-365. PubMed ID: 30719763
[TBL] [Abstract][Full Text] [Related]
2. Beneficial nonmotor effects of subthalamic and pallidal neurostimulation in Parkinson's disease.
Dafsari HS; Dos Santos Ghilardi MG; Visser-Vandewalle V; Rizos A; Ashkan K; Silverdale M; Evans J; Martinez RCR; Cury RG; Jost ST; Barbe MT; Fink GR; Antonini A; Ray-Chaudhuri K; Martinez-Martin P; Fonoff ET; Timmermann L;
Brain Stimul; 2020; 13(6):1697-1705. PubMed ID: 33038595
[TBL] [Abstract][Full Text] [Related]
3. A prospective, controlled study of non-motor effects of subthalamic stimulation in Parkinson's disease: results at the 36-month follow-up.
Jost ST; Sauerbier A; Visser-Vandewalle V; Ashkan K; Silverdale M; Evans J; Loehrer PA; Rizos A; Petry-Schmelzer JN; Reker P; Fink GR; Franklin J; Samuel M; Schnitzler A; Barbe MT; Antonini A; Martinez-Martin P; Timmermann L; Ray-Chaudhuri K; Dafsari HS;
J Neurol Neurosurg Psychiatry; 2020 Jul; 91(7):687-694. PubMed ID: 32371534
[TBL] [Abstract][Full Text] [Related]
4. Nonmotor symptoms evolution during 24 months of bilateral subthalamic stimulation in Parkinson's disease.
Dafsari HS; Silverdale M; Strack M; Rizos A; Ashkan K; Mahlstedt P; Sachse L; Steffen J; Dembek TA; Visser-Vandewalle V; Evans J; Antonini A; Martinez-Martin P; Ray-Chaudhuri K; Timmermann L;
Mov Disord; 2018 Mar; 33(3):421-430. PubMed ID: 29465787
[TBL] [Abstract][Full Text] [Related]
5. EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson's disease.
Martinez-Martin P; Reddy P; Katzenschlager R; Antonini A; Todorova A; Odin P; Henriksen T; Martin A; Calandrella D; Rizos A; Bryndum N; Glad A; Dafsari HS; Timmermann L; Ebersbach G; Kramberger MG; Samuel M; Wenzel K; Tomantschger V; Storch A; Reichmann H; Pirtosek Z; Trost M; Svenningsson P; Palhagen S; Volkmann J; Chaudhuri KR
Mov Disord; 2015 Apr; 30(4):510-6. PubMed ID: 25382161
[TBL] [Abstract][Full Text] [Related]
6. Non-motor outcomes of subthalamic stimulation in Parkinson's disease depend on location of active contacts.
Dafsari HS; Petry-Schmelzer JN; Ray-Chaudhuri K; Ashkan K; Weis L; Dembek TA; Samuel M; Rizos A; Silverdale M; Barbe MT; Fink GR; Evans J; Martinez-Martin P; Antonini A; Visser-Vandewalle V; Timmermann L; ;
Brain Stimul; 2018; 11(4):904-912. PubMed ID: 29655586
[TBL] [Abstract][Full Text] [Related]
7. Beneficial effects of bilateral subthalamic stimulation on alexithymia in Parkinson's disease.
Dafsari HS; Ray-Chaudhuri K; Mahlstedt P; Sachse L; Steffen JK; Petry-Schmelzer JN; Dembek TA; Reker P; Barbe MT; Visser-Vandewalle V; Fink GR; Timmermann L
Eur J Neurol; 2019 Feb; 26(2):222-e17. PubMed ID: 30107062
[TBL] [Abstract][Full Text] [Related]
8. Subthalamic Nucleus Deep Brain Stimulation Modulate Catecholamine Levels with Significant Relations to Clinical Outcome after Surgery in Patients with Parkinson's Disease.
Yamamoto T; Uchiyama T; Higuchi Y; Asahina M; Hirano S; Yamanaka Y; Kuwabara S
PLoS One; 2015; 10(9):e0138462. PubMed ID: 26394059
[TBL] [Abstract][Full Text] [Related]
9. Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus.
De Gaspari D; Siri C; Landi A; Cilia R; Bonetti A; Natuzzi F; Morgante L; Mariani CB; Sganzerla E; Pezzoli G; Antonini A
J Neurol Neurosurg Psychiatry; 2006 Apr; 77(4):450-3. PubMed ID: 16543520
[TBL] [Abstract][Full Text] [Related]
10. Eight-year follow-up outcome of subthalamic deep brain stimulation for Parkinson's disease: Maintenance of therapeutic efficacy with a relatively low levodopa dosage and stimulation intensity.
Jiang L; Chen W; Guo Q; Yang C; Gu J; Xian W; Liu Y; Zheng Y; Ye J; Xu S; Hu Y; Wu L; Chen J; Qian H; Fu X; Liu J; Chen L
CNS Neurosci Ther; 2021 Nov; 27(11):1366-1373. PubMed ID: 34350691
[TBL] [Abstract][Full Text] [Related]
11. Quality of life outcome after subthalamic stimulation in Parkinson's disease depends on age.
Dafsari HS; Reker P; Stalinski L; Silverdale M; Rizos A; Ashkan K; Barbe MT; Fink GR; Evans J; Steffen J; Samuel M; Dembek TA; Visser-Vandewalle V; Antonini A; Ray-Chaudhuri K; Martinez-Martin P; Timmermann L;
Mov Disord; 2018 Jan; 33(1):99-107. PubMed ID: 29150860
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes using ClearPoint interventional MRI for deep brain stimulation lead placement in Parkinson's disease.
Ostrem JL; Ziman N; Galifianakis NB; Starr PA; Luciano MS; Katz M; Racine CA; Martin AJ; Markun LC; Larson PS
J Neurosurg; 2016 Apr; 124(4):908-16. PubMed ID: 26495947
[TBL] [Abstract][Full Text] [Related]
13. Brain connectivity changes when comparing effects of subthalamic deep brain stimulation with levodopa treatment in Parkinson's disease.
Mueller K; Jech R; Růžička F; Holiga Š; Ballarini T; Bezdicek O; Möller HE; Vymazal J; Růžička E; Schroeter ML; Urgošík D
Neuroimage Clin; 2018; 19():1025-1035. PubMed ID: 30035027
[TBL] [Abstract][Full Text] [Related]
14. Subthalamic nucleus stimulation does not cause deterioration of preexisting hallucinations in Parkinson's disease patients.
Yoshida F; Miyagi Y; Kishimoto J; Morioka T; Murakami N; Hashiguchi K; Samura K; Sakae N; Yamasaki R; Kawaguchi M; Sasaki T
Stereotact Funct Neurosurg; 2009; 87(1):45-9. PubMed ID: 19174620
[TBL] [Abstract][Full Text] [Related]
15. Meta-analysis comparing deep brain stimulation of the globus pallidus and subthalamic nucleus to treat advanced Parkinson disease.
Liu Y; Li W; Tan C; Liu X; Wang X; Gui Y; Qin L; Deng F; Hu C; Chen L
J Neurosurg; 2014 Sep; 121(3):709-18. PubMed ID: 24905564
[TBL] [Abstract][Full Text] [Related]
16. Effects of deep brain stimulation of the subthalamic nucleus on freezing of gait in Parkinson's disease: a prospective controlled study.
Vercruysse S; Vandenberghe W; Münks L; Nuttin B; Devos H; Nieuwboer A
J Neurol Neurosurg Psychiatry; 2014 Aug; 85(8):871-7. PubMed ID: 24396010
[TBL] [Abstract][Full Text] [Related]
17. [Effects of bilateral deep brain stimulation in the subthalamic nucleus using two methods of target structure verification].
Goubareva NN; Fedorova NV; Bril' EV; Tomskiy AA; Gamaleya AA; Poddubskaya AA; Shabalov VA; Omarova SM
Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(11):24-30. PubMed ID: 29265083
[TBL] [Abstract][Full Text] [Related]
18. Beneficial effect of 24-month bilateral subthalamic stimulation on quality of sleep in Parkinson's disease.
Dafsari HS; Ray-Chaudhuri K; Ashkan K; Sachse L; Mahlstedt P; Silverdale M; Rizos A; Strack M; Jost ST; Reker P; Samuel M; Visser-Vandewalle V; Evans J; Antonini A; Martinez-Martin P; Timmermann L;
J Neurol; 2020 Jun; 267(6):1830-1841. PubMed ID: 32152689
[TBL] [Abstract][Full Text] [Related]
19. A comparison of indirect and direct targeted STN DBS in the treatment of Parkinson's disease-surgical method and clinical outcome over 15-year timespan.
Lahtinen MJ; Haapaniemi TH; Kauppinen MT; Salokorpi N; Heikkinen ER; Katisko JP
Acta Neurochir (Wien); 2020 May; 162(5):1067-1076. PubMed ID: 32103343
[TBL] [Abstract][Full Text] [Related]
20. Relationship between electrode position of deep brain stimulation and motor symptoms of Parkinson's disease.
Zhang F; Wang F; Li W; Wang N; Han C; Fan S; Li P; Xu L; Zhang J; Meng F
BMC Neurol; 2021 Mar; 21(1):122. PubMed ID: 33731033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
